Aktuellt
SENASTE
Redeye embraces the news that the FDA has finally granted BONESUPPORT approval for its product CERAMENT G for bone infection in the US. We expect the first sales should come by the end of Q3’22E or early Q4’22E. Furthermore, we are relieved that the approval came before July 1st, as it now allows for full capitalization of the NTAP. The delayed FDA decision has long been a wet blanket over the share, but we judge the stock will now be able to regain its positive momentum, starting today. We expect the share to react with a c.30-40% rally and climb closer to our SEK 70 Base Case in the months following.
LÄS MER
